Group 1 - L'Oréal Group and Kering Group announced a long-term strategic partnership in the luxury beauty sector, with Kering selling its beauty business to L'Oréal for €4 billion (approximately 33.3 billion RMB) [1] - L'Oréal will acquire the Creed brand and gain exclusive rights to develop perfumes and beauty products for Kering's brands such as Gucci, Bottega Veneta, and Balenciaga for a period of 50 years [1][2] - The transaction is expected to be completed in the first half of 2026, and both companies plan to explore further collaboration opportunities in luxury goods, health, and longevity through a 50-50 joint venture [1] Group 2 - Kering's beauty division, established in 2023, reported total sales of €32.3 million in 2024, a significant increase of 421% year-on-year, primarily driven by Creed [2] - Despite the growth in the beauty sector, Kering's overall sales declined by 16% year-on-year, and net profit fell by 46%, indicating financial pressure [2] - Kering's new CEO, Luca de Meo, is focused on improving the company's balance sheet, making the sale of the underperforming beauty business a necessary step [2][3] Group 3 - The partnership is expected to strengthen L'Oréal's leadership position in the luxury beauty market, leveraging the potential of brands like Gucci and Bottega Veneta [2] - Analysts believe that this collaboration will help Kering gain a larger market share in the luxury sector amid overall industry pressures [3]

Company News - China Mobile (00941.HK) reported a total operating revenue of 794.7 billion yuan for the first three quarters, a year-on-year increase of 0.4%, with a net profit of 115.4 billion yuan, up 4% [1] - As of September 30, communication service revenue was 683.1 billion yuan, a 0.8% increase year-on-year, while sales of products and others were 111.5 billion yuan, a decrease of 1.7% [1] - Mobile internet traffic increased by 8.3% year-on-year, with a mobile ARPU of 48.0 yuan [1] - Contemporary Amperex Technology Co., Ltd. (宁德时代) (03750.HK) achieved revenue of approximately 283.07 billion yuan from January to September, a year-on-year increase of 9.28%, with a net profit of approximately 49.03 billion yuan, up 36.2% [1] Financing and Buyback Dynamics - HSBC Holdings (00005.HK) repurchased 4.64 billion HKD worth of shares, totaling 4.5664 million shares, at prices ranging from 100.6 to 102.4 HKD [6] - Mengniu Dairy (02319.HK) repurchased shares worth 10.14 million HKD, totaling 700,000 shares, at prices between 14.37 and 14.52 HKD [6] - Lianyi Technology (09959.HK) repurchased shares worth 743.93 million HKD, totaling 2.45 million shares, at prices ranging from 2.97 to 3.07 HKD [7]

Core Viewpoint - Liken Resources (2245.HK) experienced a significant intraday increase of 7.62%, reaching HKD 23.72, following news of a share acquisition by JPMorgan Chase & Co. and the establishment of a framework agreement with its controlling shareholder, Likun Investment [1] Group 1: Share Acquisition - JPMorgan Chase & Co. increased its stake in Liken Resources by acquiring 3,280,264 shares at an average price of HKD 26.2808 per share, totaling approximately HKD 86.208 million [1] - Following this acquisition, JPMorgan's ownership in Liken Resources rose from 5.41% to 6.00% [1] Group 2: Framework Agreement - Liken Resources announced a framework agreement for engineering construction services with its controlling shareholder, Likun Investment [1] - The board believes that establishing a framework agreement, rather than a one-time contract, is commercially advantageous, ensuring competitive terms for stable and high-quality supply of services and materials [1] - This agreement is expected to significantly enhance the flexibility of business arrangements in line with the company's overall strategic development and growth plans [1]

Core Insights - Nanjing Pharmaceutical (600713) signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. and Guangzhou Traditional Chinese Medicine Equity Investment Partnership (Limited Partnership) [2] - Baiyunshan's subsidiary plans to acquire 144,557,431 shares from Alliance Healthcare Asia Pacific Limited, representing 11.04% of Nanjing Pharmaceutical's total shares [2] Group 1: Transaction Details - The share transfer price is set at 5.18 CNY per share, totaling approximately 748.81 million CNY [4] - Nanjing Pharmaceutical's current stock price is 4.88 CNY per share, indicating a slight premium over the transfer price [4] Group 2: Company Profiles - Baiyunshan is an A+H listed company with a market capitalization of approximately 41.3 billion CNY, engaged in the research, development, manufacturing, and sales of various pharmaceutical products [4][5] - Nanjing Pharmaceutical has a market capitalization of around 6.4 billion CNY and focuses on pharmaceutical distribution and healthcare services [6] Group 3: Strategic Implications - Baiyunshan aims to enhance business cooperation with Nanjing Pharmaceutical, optimizing its industrial layout in East China and strengthening its competitive advantage in pharmaceutical distribution [6] - The collaboration is based on principles of mutual benefit, resource sharing, and long-term strategic partnership [6]

Group 1 - The company, ShenSanda A, expressed its commitment to an inclusive and open mindset in collaborating with various industry participants [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CCIAM Future Energy Limited 信能低碳有限公司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （股份代號：145） 自願公佈 協議備忘錄 本公佈乃由信能低碳有限公司（「本公司」）自願作出，以向本公司股東及潛在投 資者提供與本公司及其附屬公司（「本集團」）最新業務發展有關的資料。 協議備忘錄 本公司的全資附屬公司信能工程為一間根據香港法律正式註冊成立的公司。其主 要從事節能業務。 有關KEY ACTION的資料 Key Action為一間根據英屬處女群島法律正式註冊成立的公司，主要從事投資控股。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月四日，本公司 的全資附屬公司信能工程（中國）有限公司（「信能工程」）與Key Action Limited （「Key Action」）訂立協議備忘錄（「協議備忘錄」）。 根據協議備忘錄，信能工程同意與Key Act ...

Group 1 - The company reported a profit of approximately RMB 306.5 million for the first half of 2025, reversing a loss of RMB 247.3 million from the same period in 2024, primarily due to increased other income and reduced sales, distribution, R&D, and administrative expenses, partially offset by decreased revenue [1] - Adjusted loss decreased by RMB 178.9 million or 82.7% to RMB 37.4 million for the first half of 2025, compared to an adjusted loss of RMB 216.2 million for the first half of 2024 [1] - The adjusted loss was derived from the reported profit of RMB 59.2 million, excluding the impact of share-based payment expenses, write-offs of right-of-use assets, and lease termination gains/losses [1] Group 2 - The company began a strategic partnership with Baiyang Pharmaceutical in August 2025, appointing its subsidiaries as exclusive contract sales organizations for marketing services and distribution in mainland China, Hong Kong, and Macau, with a strategic cooperation fee of RMB 50 million [2] - Baiyang Pharmaceutical's subsidiary subscribed for 74,971,468 shares of the company, representing 14.99% of the enlarged issued share capital, for a total consideration of approximately HKD 100 million [2] - Despite challenges in the first half of 2025, the company remains optimistic for the second half, focusing on streamlining its product line and enhancing capital efficiency, expecting improved performance through deeper collaboration with Baiyang Pharmaceutical [2]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Bentley Huajun (Hainan) Food Co., Ltd. to explore potential business collaboration in product sales and marketing in mainland China and Hong Kong [1] Group 1: Strategic Cooperation Agreement - The agreement includes the establishment of a subsidiary, China Bentley Investment Co., Ltd., to jointly develop the Chinese sauce-flavored liquor market with Bentley Huajun [1] - Bentley Huajun will primarily focus on investments in wine, healthcare, artificial intelligence, high-tech agriculture, and supply chain, while the company will handle brand promotion and marketing for the liquor business [1] - Specific details and terms of the business development are subject to further negotiation between the two parties [1] Group 2: Business Expansion and Opportunities - The group is actively seeking joint ventures, business collaborations, and investment opportunities in the Greater Bay Area [1] - The board believes that the strategic cooperation presents a valuable opportunity to expand the company's revenue sources by broadening its business scope [1] - By leveraging Bentley Huajun's expertise in business and sales with the company's marketing services, the partnership is expected to create synergies for promoting and developing the business in the Chinese market [1]

Core Viewpoint - The renewal of the agreement between Baibang Technology and Apple is aligned with the company's strategic development direction and is expected to enhance business scope and operational performance [1] Group 1 - Baibang Technology's wholly-owned subsidiary, Shanghai Baibang, has renewed the "Apple Authorized Service Provider Agreement" with Apple Computer Trading (Shanghai) Co., Ltd. [1] - The contract has been extended until June 30, 2029 [1] - This renewal is beneficial for expanding the company's business range and improving operational performance [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with its major shareholders to enhance operational efficiency and pursue high-quality development through resource sharing and collaboration [2][3]. Group 1 - The agreement involves the termination of a previous cooperation agreement signed on May 27, 2016, and the acquisition of 100,000,000 shares (28.06% of total shares) held by the original controlling shareholder, Dalian Friendship Group [2]. - The parties have agreed to leverage their respective advantages to support Dalian Friendship in improving its operational performance and achieving high-quality growth [2][3]. Group 2 - The cooperation will include diversified and in-depth collaboration in equity and business areas, such as increasing shareholding in Dalian Friendship and engaging in retail and new retail business partnerships [3]. - Both parties aim to utilize their resources and industrial strengths to enhance cooperation, empower each other, and achieve win-win development [3].